Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin Phosphate Foam, 1%, the generic version of Evoclin1 Foam, 1%, of Mylan pharmaceuticals Inc. According to IQVIATM sales data for the 12 months ending July 2021, the Evoclin Foam, 1%, market achieved annual sales of approximately US $ 12 million.

Glenmark’s current portfolio consists of 173 products authorised for distribution in the U.S. marketplace and 47 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio